Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rFVIII-FS Prophylaxis Regimens in Pediatric Hemophilia A
NCT00632814Phase 4Completed
- Sponsor
- Bayer
- Start
- Jun 2007
- Primary completion
- Sep 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of octocog alfa in hemophilia A (3 arms), sponsored by Bayer. Primary endpoint: Percentage of Participants With Less Than 2 Joint Bleeds During the 9-month Treatment Period. Started Jun 2007; status: completed.
02
Drugs
octocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT00632814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00632814.